Table 2.
Annualized vitreous haze changes
| Mean annualized vitreous haze change score (95% confidence interval) | P value for subgroup analysis | |
|---|---|---|
| MS patients, overall | −0.019/year (−0.031 to −0.007) | Reference |
| Healthy controls | −0.0026/year (−0.028 to 0.023) | 0.256 |
| Type of MS | ||
| Relapsing–remitting MS | −0.014/year (−0.028 to −0.0002) | Reference |
| Secondary progressive MS | −0.021/year (−0.053 to −0.011) | 0.626 |
| Primary progressive MS | −0.044/year (−0.081 to −0.007) | 0.076 |
| History of MSON | ||
| MSON eyes | −0.016/year (−0.037 to 0.005) | Reference |
| MSNON eyes | −0.021/year (−0.036 to −0.006) | 0.850 |
| Use of disease modifying therapy | ||
| Current use | −0.007/year (−0.026 to 0.012) | Reference |
| Past | −0.027/year (−0.053 to −0.0003) | 0.208 |
| Never | −0.023/year (−0.042 to −0.005) | 0.198 |
| Relapses in the year following baseline assessment | ||
| Yes | −0.035/year (−0.079 to 0.009) | Reference |
| No | −0.018/year (−0.030 to −0.005) | 0.604 |
MS, multiple sclerosis; MSNON, no history of MS associated optic neuritis; MSON, MS associated optic neuritis.